Vasculitis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030

Industry Outlook

The vasculitis treatment market expected to reach US$ 744.12 Mn by 2030 from US$ 407.8 Mn in 2021 and projected to exhibit a steady compound annual growth rate (CAGR) of 5.7% during the forecast period from 2022 to 2030. According to Vasculitis Foundation 2019 report, the global prevalence of vasculitis is 1-9 per 100,000 people. Vasculitis shows high degree of incidence in the Caucasian population and is widely prevalent in the Scandinavian countries. Earlier cyclophosphamide was considered as the first line of treatment for all types of vasculitis. In 2010, United States Food and Drug Administration (USFDA) had approved rituximab for the treatment of vasculitis along with prednisolone. Pharmaceutical and biotechnology industries are constantly striving to achieve a targeted drug therapy approach for the treatment of vasculitis majorly focusing on monoclonal antibodies such as tocilizumab, mepolizumab and infliximab. CCX168 developed by ChemoCentryx, currently under phase II clinical trials is an immunosuppressant is projected to enter the market by 2021 and anticipated to register impressive growth during the forecast period for the treatment of ANCA associated vasculitis. In 2020, North America held the largest market share in the vasculitis treatment market on account of the developed healthcare infrastructure, increasing public health awareness resulting in early vasculitis diagnosis. North America is domicile to key players engaged in the treatment of vasculitis disease, contributes towards dominance of North America in this market. Asia Pacific will register significant growth during the forecast period owing to huge geriatric population suffering with large vessel vasculitis, and supportive regulatory environment for the treatment of vasculitis disease.

Better Clinical Outcomes in Vasculitis Treatment Will Contribute To the Biologics Segment Growth

Currently biologics are leading the market by drug class segment and will continue to showcase excellent growth during the forecast period. In 2010, USFDA gave approval to rituximab for the treatment of vasculitis disease in combination with prednisolone. The dosage regimen currently postulated for rituximab throughout the globe is 4+2 protocol. In 2020, Biologics comprised of 38.98% share in the drug class segment on account of better drug safety & efficacy and rising prevalence of antineutrophil cytoplasmic autoantibodies (ANCA) associated renal vasculitis in elderly population. The only limitation of using rituximab therapy is its high cost, which hinders treatment in poor nations. Cyclophosphamide are used in patients showing resistance to rituximab therapy and its relatively low treatment cost contributes to its market growth in developing nations.

Accurate Diagnosis of Small Vessel Vasculitis to Record Highest Double Digit CAGR during the Forecast Period

The challenge that usually occur during the diagnosis of vasculitis is its overlapping symptoms with other inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, etc. The ambiguity occurs due to non-specificity of serological markers and irrational tissue biopsy. The chief inflammatory mediator that occurs in the vasculitis disease onset is leucocytes. The factors responsible for the accurate diagnosis of vasculitis is the technological advancement in the diagnostic kits and availability of skilled workforce to perform the diagnosis. In 2020, large vessel vasculitis occupied 45% share in the overall vasculitis disease epidemiology. The key attributes favoring the dominance of large vessel vasculitis are the rising prevalence of immunocompromised patients and medicines related adverse events encountered in the Caucasian populations. Small vessel vasculitis will be showcasing impressive growth during the forecast period owing to the increasing number of blood vessel aneurysm cases encountered in the Mongolian population and rampant growth in the reported cases of small vessel vasculitis initiated due to pesticide and chemical exposure.

Increasing public health awareness in Asia Pacific to set the stage for swift growth during the forecast period

In 2021, North America occupied 35.96% of the global market share for vasculitis treatment. The key factors responsible for the North America market growth are rising prevalence of large vessel vasculitis, presence of key players such as Bristol Myers Squibb Company, Celgene Corporation etc., and existence of advanced healthcare facilities. Asia Pacific will be the fastest growing market on account of large geriatric population suffering with small vessel vasculitis, enhanced funding by the pharmaceutical companies in the R&D segment and rising public health awareness resulting in early diagnosis and treatment.

Market assessment is performed in order to understand the prevailing market trends in the vasculitis treatment market. Market estimation is done by providing the compounded annual growth rate (CAGR) and data forecast for 2022-2030. Product portfolio is helpful in giving information of the FDA approved drugs currently prescribed for the treatment of vasculitis disease. Strategic collaboration, merger and acquisition among the key players for developing impressive product pipeline are mentioned in the business strategy section. The key players currently engaged in the Vasculitis Treatment market are F.Hoffman La-Roche Ltd., AstraZeneca, Baxter International, Bristol Myers Squibb Company, Celgene Corporation, ChemoCentryx, Daiichi Sankyo, Eli Lilly & Company, GlaxosmithKline Plc, Merck & Co., and Novartis AG.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Vasculitis Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Vasculitis Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug

• Biologics
• Rituximab
• Infliximab
• Adalimumab
• Corticosteroids
• Prednisone
• Methylprednisolone
• Immunosuppressant
• Pipeline Analysis
• Tabular Representation of Phase I and Phase II Drugs

Disease Condition

• Large Vessel Vasculitis
• Medium Vessel Vasculitis
• Small Vessel Vasculitis

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Vasculitis Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2030.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Vasculitis Treatment market?
• Which is the largest regional market for Vasculitis Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Vasculitis Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Vasculitis Treatment market worldwide?

This product will be delivered within 2 business days.